Quintiles named Asia Pacific CRO company of the year

Skip to Navigation


  • Published: Oct 21, 2015
  • Author: Jon Evans
  • Source: Quintiles
  • Channels: Detectors / Sample Preparation / Gas Chromatography / Electrophoresis / HPLC / Proteomics & Genomics / Laboratory Informatics / Ion Chromatography / UV/Vis Spectroscopy / Atomic / Proteomics / Chemometrics & Informatics / X-ray Spectrometry / Raman / Base Peak / MRI Spectroscopy / Infrared Spectroscopy / NMR Knowledge Base

The business research and consulting firm Frost & Sullivan has named Quintiles as its Asia Pacific Contract Research Organization (CRO) company of the year.

“Quintiles is the clear market leader in the Asia Pacific CRO landscape,” said Rhenu Bhuller, partner, healthcare, at Frost & Sullivan. “Asia Pacific is a strong focus area for multinational CROs and we evaluated the top five on two key factors – ‘visionary innovation and performance’ and ‘customer impact’. Quintiles scored highly in all criteria, and particularly so in ‘pioneering best practices’ and ‘addressing biopharma’s unmet needs’.

“For example, Quintiles launched a dedicated medical devices unit in Asia Pacific in 2015 that leverages the expertise of Novella Clinical, a Quintiles company. It also introduced a custom-tailored set of solutions for Asia Pacific emerging biopharma. Both of these are fast-growing market sectors and ones in which government and industry are trying to build capabilities. Quintiles is well-positioned to support this growth.”

Frost & Sullivan also cited Quintiles’ continued expansion of services in Asia Pacific, particularly in Greater China, Japan and South Korea, and its use of innovative technologies to improve efficiency and quality.

“This honor belongs to our 10,000 plus employees across Asia Pacific who work every day to improve our customers’ probability of success,” said Anand Tharmaratnam, Quintiles’ president and head of Asia Pacific. “I believe Asia is entering a new era – one marked by global leadership in biopharma R&D and by diffusion of Asian innovation to global markets.

“With 60% of the world’s population, there is tremendous need in Asia Pacific for medicines that will deliver better value and improve patient outcomes. We’re very proud to receive this honor in recognition of our efforts to help achieve that.”

Social Links

Share This Links

Bookmark and Share


Suppliers Selection
Societies Selection

Banner Ad

Click here to see
all job opportunities

Copyright Information

Interested in separation science? Visit our sister site separationsNOW.com

Copyright © 2019 John Wiley & Sons, Inc. All Rights Reserved